- Incremental Data to be Presented at ASCO GI Symposia Continue to Support Picoplatin as Neuropathy-Sparing Alternative to Oxaliplatin in First-Line Colorectal Cancer Treatment -
SOUTH SAN FRANCISCO, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced updated efficacy and safety data from its randomized, controlled Phase 2 clinical trial of picoplatin in patients with metastatic colorectal cancer (CRC). Results continue to suggest that picoplatin, given once every four weeks in combination with 5-fluorouracil and leucovorin (FOLPI), is associated with less frequent and less severe neurotoxicity than oxaliplatin given in combination with 5-fluorouracil and leucovorin in the modified FOLFOX-6 regimen (FOLFOX). Results also continue to indicate that both regimens have similar anti-tumor activity in first-line metastatic CRC. Net sales in 2007 in the US for Eloxatin (oxaliplatin) were approximately $1.3 billion.
"These new data continue to suggest that picoplatin is an active platinum agent in colorectal cancer, but without the significant neuropathy associated with currently marketed platinums," said Richard Goldberg, M.D., associate director of clinical research for the
Picoplatin, the Company's lead product candidate, is a new generation platinum-based chemotherapy agent with the potential to become a platform product addressing mult
|SOURCE Poniard Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved